Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 24.90%621.25M | 29.40%429.93M | 38.46%296.18M | 122.05%186.07M | 36.42%497.41M | 20.09%332.26M | 16.55%213.91M | -2.54%83.79M | -2.94%364.62M | -0.21%276.67M |
Operating revenue | 24.90%621.25M | 29.40%429.93M | 38.46%296.18M | 122.05%186.07M | 36.42%497.41M | 20.09%332.26M | 16.55%213.91M | -2.54%83.79M | -2.94%364.62M | -0.21%276.67M |
Total operating cost | 17.64%633.74M | 16.55%446.56M | 25.41%307.03M | 64.59%170.78M | 32.68%538.72M | 18.09%383.14M | 19.80%244.83M | 11.20%103.76M | 24.57%406.03M | 37.60%324.44M |
Operating cost | 13.65%383.43M | 7.90%257.61M | 15.47%178.6M | 76.66%109.12M | 31.94%337.37M | 19.86%238.75M | 18.07%154.68M | 2.24%61.77M | -1.11%255.71M | 7.07%199.2M |
Operating tax surcharges | 27.18%5.39M | 67.13%3.83M | 100.03%1.78M | 148.96%1.01M | 68.93%4.24M | 52.58%2.29M | -22.24%890.25K | 23.23%406.06K | 17.79%2.51M | 3.66%1.5M |
Operating expense | 32.51%50.68M | 49.41%38.36M | 45.95%24.35M | 61.26%12.32M | 38.21%38.25M | 31.74%25.67M | 36.76%16.69M | 55.49%7.64M | 19.32%27.67M | -3.92%19.49M |
Administration expense | 7.97%108.38M | 6.64%83.19M | 19.08%58.54M | 30.87%28.54M | 10.58%100.38M | -6.85%78.01M | 4.22%49.16M | 0.17%21.81M | 288.36%90.78M | 462.14%83.75M |
Financial expense | 61.55%12.77M | 74.05%9.31M | 104.84%6.06M | 49.55%2.98M | 1,171.91%7.91M | 1,944.26%5.35M | 1,508.14%2.96M | 2,406.67%2M | 185.18%621.59K | 186.26%261.57K |
-Interest expense (Financial expense) | 59.57%12.86M | 70.42%9.37M | 97.59%6.08M | 82.04%2.39M | 287.71%8.06M | 386.54%5.5M | 263.30%3.08M | 203.14%1.31M | 165.91%2.08M | 114.94%1.13M |
-Interest Income (Financial expense) | 41.73%-249.68K | 50.95%-178.56K | 55.18%-129.9K | 63.79%-35.33K | 76.87%-428.48K | 72.67%-364.02K | 78.24%-289.81K | 83.27%-97.58K | -7.14%-1.85M | -27.39%-1.33M |
Research and development | 44.50%73.09M | 64.11%54.26M | 84.25%37.69M | 65.67%16.8M | 75.94%50.58M | 63.37%33.06M | 56.61%20.46M | 69.90%10.14M | 48.08%28.75M | 50.81%20.24M |
Credit Impairment Loss | 24.56%-9.37M | -157.86%-7.62M | -1,412.34%-4.82M | -242.24%-3.47M | -143.42%-12.42M | -57.07%-2.95M | 79.55%-318.8K | 264.88%2.44M | -327.57%-5.1M | -20.07%-1.88M |
Asset Impairment Loss | 18.79%-1.73M | -440.30%-1.62M | -359.14%-1.56M | ---105K | -34.86%-2.13M | 212.87%475.01K | 19.37%-339.34K | ---- | -529.12%-1.58M | -128.73%-420.86K |
Other net revenue | ||||||||||
Fair value change income | --4.63M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -95.99%347.36K | --336.02K |
Invest income | 139.42%14.53M | 1,519.71%14.02M | 53,649.67%14.5M | --15.53M | 2,331.90%6.07M | 252.08%865.68K | -110.34%-27.08K | ---- | 143.62%249.51K | 140.07%245.87K |
-Including: Investment income associates | -158.12%-455.41K | -240.75%-905.41K | -224.62%-560.27K | ---57.04K | 224.55%783.56K | --643.27K | --449.56K | ---- | ---629.09K | ---- |
Asset deal income | -15,530.40%-2.31M | 221.38%12.12K | 523.85%12.12K | ---394.99K | 719.52%14.94K | --3.77K | --1.94K | ---- | -92.44%1.82K | ---- |
Other revenue | 7.86%4.28M | 161.78%3.65M | 82.58%2.29M | 78.67%1.48M | 175.87%3.97M | 31.39%1.39M | 125.82%1.25M | 159.68%826.73K | -31.06%1.44M | -5.38%1.06M |
Operating profit | 94.63%-2.46M | 83.97%-8.19M | 98.61%-421.67K | 269.69%28.33M | 0.53%-45.81M | -5.53%-51.1M | -39.38%-30.34M | -98.70%-16.7M | -177.87%-46.05M | -218.25%-48.43M |
Add:Non operating Income | -48.94%108.37K | -99.27%462.84 | -99.74%64.77 | -98.23%3.67K | 1,237.30%212.23K | 127.98%63.02K | 268.03%25.15K | 6,824.30%207.73K | -99.76%15.87K | -99.59%27.64K |
Less:Non operating expense | 18.99%248.33K | 6.85%138.8K | -44.85%64.72K | -48.50%38.95K | -89.75%208.7K | -93.56%129.89K | -94.15%117.35K | 1,609.74%75.63K | 1,428.09%2.04M | 1,423.90%2.02M |
Total profit | 94.32%-2.6M | 83.72%-8.33M | 98.40%-486.32K | 270.83%28.29M | 4.71%-45.8M | -1.49%-51.17M | -28.05%-30.43M | -97.09%-16.56M | -173.38%-48.07M | -206.03%-50.42M |
Less:Income tax cost | 36.18%-7.01M | 87.56%-1.67M | 64.04%-3.02M | 390.27%3.24M | 5.18%-10.99M | -22.92%-13.39M | -98.79%-8.4M | 161.68%660.08K | -268.55%-11.59M | -320.34%-10.89M |
Net profit | 112.68%4.41M | 82.36%-6.66M | 111.51%2.54M | 245.49%25.06M | 4.56%-34.81M | 4.41%-37.78M | -12.75%-22.03M | -134.85%-17.22M | -162.22%-36.48M | -192.77%-39.52M |
Net profit from continuing operation | 112.68%4.41M | 82.36%-6.66M | 111.51%2.54M | 245.49%25.06M | 4.56%-34.81M | 4.41%-37.78M | -12.75%-22.03M | -134.85%-17.22M | -162.22%-36.48M | -192.77%-39.52M |
Less:Minority Profit | 757.58%17M | 287.41%10.29M | 355.57%8.41M | 297.60%9.81M | 146.81%1.98M | -44.24%-5.49M | -23.06%-3.29M | -258.84%-4.97M | -176.45%-4.23M | -172.68%-3.81M |
Net profit of parent company owners | 65.80%-12.58M | 47.49%-16.95M | 68.68%-5.87M | 224.38%15.25M | -14.12%-36.79M | 9.60%-32.29M | -11.11%-18.74M | -106.02%-12.26M | -160.73%-32.24M | -195.58%-35.72M |
Earning per share | ||||||||||
Basic earning per share | 65.00%-0.14 | 48.57%-0.18 | 70.00%-0.06 | 223.08%0.16 | -14.29%-0.4 | 10.26%-0.35 | -11.11%-0.2 | -116.67%-0.13 | -154.69%-0.35 | -182.98%-0.39 |
Diluted earning per share | 65.00%-0.14 | 48.57%-0.18 | 70.00%-0.06 | 223.08%0.16 | -14.29%-0.4 | 10.26%-0.35 | -11.11%-0.2 | -116.67%-0.13 | -154.69%-0.35 | -182.98%-0.39 |
Other composite income | -13.53K | -5.98K | ||||||||
Other composite income of parent company owners | ---13.53K | ---5.98K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Total composite income | 112.64%4.4M | 82.34%-6.67M | 111.51%2.54M | 245.49%25.06M | 4.56%-34.81M | 4.41%-37.78M | -12.75%-22.03M | -134.85%-17.22M | -162.22%-36.48M | -192.77%-39.52M |
Total composite income of parent company owners | 65.77%-12.6M | 47.47%-16.96M | 68.68%-5.87M | 224.38%15.25M | -14.12%-36.79M | 9.60%-32.29M | -11.11%-18.74M | -106.02%-12.26M | -160.73%-32.24M | -195.58%-35.72M |
Total composite income of minority owners | 757.58%17M | 287.41%10.29M | 355.57%8.41M | 297.60%9.81M | 146.81%1.98M | -44.24%-5.49M | -23.06%-3.29M | -258.84%-4.97M | -176.45%-4.23M | -172.68%-3.81M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | -- | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.